A physician consultation is required to determine if this combination aligns with your health profile and goals
The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for estrogen-progestin compared with placebo
Head-to-Head Superiority (SURMOUNT-5): The SURMOUNT-5 trial, with detailed results published in The New England Journal of Medicine on May 11, 2025, directly compared Tirzepatide (Zepbound) with semaglutide (Wegovy)
Simple Meal Plan for Tirzepatide and Semaglutide Patients Heres an easy, well-balanced meal plan example to help structure your day
Ongoing review helps us keep that balance
Es importante que sepas que este formato est reservado para usos clnicos muy especficos y siempre bajo estricta supervisin mdica